

LITERATÚRA

1. Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. *The American journal of medicine*. 1984;77(4):633-638. Available from: [https://doi.org/10.1016/0002-9343\(84\)90353-x](https://doi.org/10.1016/0002-9343(84)90353-x).
2. Nuttall FQ. Gynecomastia as a physical finding in normal men. *The Journal of clinical endocrinology and metabolism*. 1979;48(2):338-340. Available from: <https://doi.org/10.1210/jcem-48-2-338>.
3. Ordaz DL, Thompson JK. Gynecomastia and psychological functioning: A review of the literature. *Body Image*. 2015;15:141-148. Available from: <https://doi.org/10.1016/j.bodyim.2015.08.004>.
4. Miklisova D, Verbat M, Sutakova E, et al. Surgical treatment of Bicalutamide-induced gynecomastia. In: *PlastSurgeon.com* [on-line]. 2023 May [cited 2023 August 06]. Available from: <https://plastsurgeon.com/case-competition-overview/case-competition-2023/case-17-surgical-excision-of-bicalutamide-induced-gynecomastia/>.
5. Fagerlund A, Cormio L, Palangi L, et al. Gynecomastia in Patients with Prostate Cancer: A Systematic Review. *PLoS one*. 2015;10(8):e0136094. Available from: <https://doi.org/10.1371/journal.pone.0136094>.
6. Di Lorenzo G, Autorino R. Bicalutamide-Induced Gynecomastia: Do We Have the Answer? *European Urology*. 2007;52(1):5-8. Available from: <https://doi.org/10.1016/j.eururo.2007.01.063>.
7. Ritter JM, Robinson E, Fullerton J, et al. Rang & Dale's Pharmacology (9th ed.) [on-line]. Elsevier – OHCE; 2018. Available from: <https://bookshelf.health.elsevier.com/books/9780702074455>.
8. Souhrn údajů o přípravku Bicaluplex – Sukl.cz. Státní ústav pro kontrolu léčiv. (n.d.-a). [on-line]. Available from: <https://prehledy.sukl.cz/prehledy/v1/dokumenty/16464>.
9. Haynes BA, Mookadam F. Male gynecomastia. *Mayo Clinic proceedings*. 2009;84(8):672. Available from: [https://doi.org/10.1016/S0025-6196\(11\)60515-6](https://doi.org/10.1016/S0025-6196(11)60515-6).
10. Jeunemaitre X, Kreft-Jais C, Chatellier G, et al. Long-term experience of spironolactone in essential hypertension. *Kidney Int Suppl*. 1988;26:S14-S17. Available from: <https://pubmed.ncbi.nlm.nih.gov/3199684/>.
11. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. *Pharmacotherapy*. 2009;29(1):64-73. doi:10.1592/phco.29.1.64.
12. Molitch ME. Medication-induced hyperprolactinemia. *Mayo Clin Proc*. 2005;80(8):1050-1057. doi:10.4065/80.8.1050.
13. Mendhekar DN, Andrade CR. Unilateral gynecomastia induced by risperidone in a geriatric male patient. *Indian J Med Sci*. 2005;59(8):361-362.
14. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. *Drugs*. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003.
15. Mabini R, Wergowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. *Psychiatr Serv Wash DC*. 2000;51(8):983-985. doi:10.1176/appi.ps.51.8.983.
16. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. *Pharmacopsychiatry*. 1999;32(1):41. doi:10.1055/s-2007-979187.
17. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. *J Clin Psychopharmacol*. 1999;19(1):57-61. doi:10.1097/00004714-199902000-00011.
18. Shahi MK, Kar SK. Asymmetric, Tender Gynecomastia Induced by Olanzapine in a Young Male. *Indian J Psychol Med*. 2017;39(2):215-216. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385759/>.
19. Aiman U, Haseen MA, Rahman SZ. Gynecomastia: An ADR due to drug interaction. *Indian journal of pharmacology*. 2009;41(6):286-287. Available from: <https://doi.org/10.4103/0253-7613.59929>.
20. He B, Carleton B, Etminan M. Risk of Gynecomastia with Users of Proton Pump Inhibitors. *Pharmacotherapy*. 2019;39(5):614-618. Available from: <https://doi.org/10.1002/phar.2245>.
21. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. *Pharmacotherapy*. 2012;32(12):1123-1140. doi:10.1002/phar.1138.
22. Wilt TJ, Macdonald R, Hagerty K, et al. 5- α -Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. *BJU Int*. 2010;106(10):1444-1451. doi:10.1111/j.1464-410X.2010.09714.x.
23. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. *Antimicrob Agents Chemother*. 1981;19(6):1073-1074. doi:10.1128/AAC.19.6.1073.
24. Molitch ME. Medication-induced hyperprolactinemia. *Mayo Clin Proc*. 2005;80(8):1050-1057. doi:10.4065/80.8.1050.
25. Klein JJ, Segal RL, Warner RRP. Galactorrhea Due to Imipramine. Available from: <http://dx.doi.org/10.1056/NEJM196409032711008>. doi:10.1056/NEJM196409032711008.
26. Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. *Br J Psychiatry J Ment Sci*. 1985;147:87-88. doi:10.1192/bjp.147.1.87.
27. Arroyo H. Gynecomastia induced by a monoamine oxidase inhibitor. *Presse Med*. 1966;74(34):1764.
28. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. *Am J Psychiatry*. 1993;150(8):1269-1270. doi:10.1176/ajp.150.8.1269a.
29. Hall MJ. Breast tenderness and enlargement induced by sertraline. *Am J Psychiatry*. 1994;151(9):1395-1396. doi:10.1176/ajp.151.9.1395b.
30. Karakurt F, Kargili A, Uz B, et al. Venlafaxine-induced gynecomastia in a young patient: a case report. *Clin Neuropharmacol*. 2009;32(1):51-52. doi:10.1097/WNF.0B013E3181679126.
31. Weydt P, Schönfeldt-Lecuona CJ, Gahr M, et al. Hypogonadism and gynecomastia with duloxetine. *Pharmacopsychiatry*. 2011;44(2):77. doi:10.1055/s-0031-1271684.
32. Damsa C, Bumb A, Bianchi-Demicheli F, et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a critical evaluation of the literature. *Eur J Clin Psychiatry*. 2004;65(8):1064-1068. doi:10.4088/jcp.v65n0806.
33. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. *Eur J Clin Pharmacol*. 2015;71(5):569-578. doi:10.1007/s00228-015-1835-x.
34. European database of suspected adverse drug reaction reports [on-line]. Available from: http://www.adrreports.eu/en/search_subst.html#. [cited 2023 October 15].
35. Swerdlow RS. MACP Gynecomastia: Etiology, Diagnosis, and Treatment [on-line]. Endotext; 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279105/#:~:text=There%20are%203%20classes%20of,such%20as%20letrozole%20and%20anastrozole>.
36. Mett TR, Pfeiler PP. Surgical treatment of gynecomastia: a standard of care in plastic surgery. *European Journal of Plastic Surgery*. 2020;43:389-398. Available from: <https://link.springer.com/article/10.1007/s00238-019-01617-8#ref-CR1>.
37. More Men Undergo Plastic Surgery as the Daddy-Do-Over Trend Rises in Popularity. *American Society of Plastic Surgeons*, 2018 National Clearinghouse of Plastic Surgery Available from: <https://www.plasticsurgery.org/news/press-releases/more-men-undergo-plastic-surgery-as-the-daddy-do-over-trend-rises-in-popularity>.
38. He W, Wei W. A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia. *BMC Endocrine Disorders*. 2023;Article number: 62. Available from: <https://bmccendocrdisord.biomedcentral.com/articles/10.1186/s12902-023-01310-9#:~:text=In%20one%20cohort%20study%2C%20TAM,than%2012%20months%20%5B12%5D>.
39. Fricke A, Lehner GM, Stark GB, et al. Long-Term Follow-up of Recurrence and Patient Satisfaction After Surgical Treatment of Gynecomastia. *Aesthetic plastic surgery*. 2017;41(3):491-498. Available from: <https://doi.org/10.1007/s00266-017-0827-x>.